
Muscle-Preserving Obesity Drug Market Projected to Surpass $30B by 2035
Jun 21, 2025 02:02 am UTC| Business Health
The race to develop muscle-preserving treatments alongside popular obesity drugs like Eli Lillys (NYSE:LLY) Zepbound and Novo Nordisks (NYSE:NVO) Wegovy is gaining momentum, with analysts at TD Cowen forecasting sales...

Australia’s TGA Sues News Corp, Mamamia Over Medicinal Cannabis Ads
Jun 20, 2025 04:17 am UTC| Business Law Health
Australias health regulator, the Therapeutic Goods Administration (TGA), has launched legal action against News Corp Australia-owned News Life Media, Mamamia.com.au, AG Therapeutics, and public relations firm Straight Up...

Kennedy's Vaccine Panel Overhaul Sparks Expert Backlash and Safety Concerns
Jun 17, 2025 01:56 am UTC| Politics Health Governance
U.S. Health Secretary Robert F. Kennedy Jr.s recent dismissal of all 17 members of the CDCs Advisory Committee on Immunization Practices (ACIP) has triggered a strong backlash from vaccine experts. The ousted panelists...

Roche Halts Elevidys Dosing in Some Duchenne Patients After Fatalities
Jun 16, 2025 09:21 am UTC| Business Health
Roche (SIX:ROG) shares dropped 2% on Monday after the company paused dosing of its gene therapy Elevidys in non-ambulatory patients with Duchenne muscular dystrophy following two deaths caused by acute liver failure. In a...

RFK Jr. Shakes Up CDC Vaccine Panel Amid Political Tensions
Jun 14, 2025 00:45 am UTC| Politics Governance Health
U.S. Health and Human Services Secretary Robert F. Kennedy Jr. is facing backlash after firing all 17 members of the CDCs Advisory Committee on Immunization Practices (ACIP) and replacing them with eight new members,...

FDA Delays KalVista’s Sebetralstat Decision Amid Workload Strain
Jun 14, 2025 00:36 am UTC| Governance Business Health
KalVista Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has extended its review of sebetralstat, an investigational treatment for hereditary angioedema (HAE), due to internal workload challenges...

FDA Expands Moderna’s RSV Vaccine Use to At-Risk Adults Aged 18–59
Jun 13, 2025 02:57 am UTC| Business Health
The U.S. Food and Drug Administration (FDA) has expanded the use of Modernas (NASDAQ:MRNA) RSV vaccine, mRESVIA, to adults aged 18 to 59 who are at increased risk of respiratory syncytial virus (RSV) disease. This marks...